Quotient (QTNT) Stock Price
Quotient Price
Revenue has compounded at 13.0% per year over the past 11 years to 38.51 M USD. Quotient's net margin stands at -324.9%, up from -332.9% several years earlier. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
Quotient stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Quotient over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Quotient stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Quotient's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Quotient Price |
|---|
Quotient Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Quotient Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.00 | 12.00 | 14.00 | 19.00 | 18.00 | 18.00 | 22.00 | 24.00 | 29.00 | 32.00 | 43.00 | 38.00 | 39.00 | 54.00 | 102.00 | 146.00 |
| – | 20.00 | 16.67 | 35.71 | -5.26 | – | 22.22 | 9.09 | 20.83 | 10.34 | 34.38 | -11.63 | 2.63 | 38.46 | 88.89 | 43.14 |
| 40.00 | 41.67 | 50.00 | 57.89 | 44.44 | 44.44 | 50.00 | 58.33 | 37.93 | 43.75 | 53.49 | 36.84 | 36.84 | 36.84 | 36.84 | 36.84 |
| 4.00 | 5.00 | 7.00 | 11.00 | 8.00 | 8.00 | 11.00 | 14.00 | 11.00 | 14.00 | 23.00 | 14.00 | 14.37 | 19.89 | 37.58 | 53.79 |
| -4.00 | -3.00 | -4.00 | -8.00 | -29.00 | -49.00 | -75.00 | -67.00 | -78.00 | -80.00 | -82.00 | -92.00 | -94.00 | -76.00 | -85.00 | -97.00 |
| -40.00 | -25.00 | -28.57 | -42.11 | -161.11 | -272.22 | -340.91 | -279.17 | -268.97 | -250.00 | -190.70 | -242.11 | -241.03 | -140.74 | -83.33 | -66.44 |
| – | – | – | -0.01 | -0.06 | -0.03 | -0.09 | -0.08 | -0.11 | -0.10 | -0.11 | -0.13 | -6.65 | -4.87 | -0.12 | -0.15 |
| – | – | – | 150.00 | 490.00 | -44.07 | 157.58 | -3.53 | 28.05 | -2.86 | 5.88 | 15.74 | 5,218.40 | -26.73 | -97.64 | 26.09 |
| 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 | 135.68 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Quotient generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Quotient retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Quotient's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Quotient has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Quotient's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Quotient stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Quotient Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Quotient business model & stock analysis
Quotient SWOT Analysis
Strengths
1. Unique Technology: Quotient Ltd possesses a proprietary technology platform that allows for rapid, accurate, and cost-effective testing of blood samples.
2. Strong Intellectual Property: The company holds a significant number of patents and licenses, providing a competitive advantage and barriers to entry for potential competitors.
3. Established Market Presence: Quotient Ltd has a strong presence in the global diagnostic testing market, with a wide customer base including hospitals, clinical laboratories, and blood banks.
Weaknesses
1. Dependence on Key Customers: Quotient Ltd relies heavily on a few major customers for a significant portion of its revenue, which exposes it to the risk of losing key accounts.
2. Limited Product Portfolio: The company's product offering is currently focused on the immunoassay diagnostics segment, which may limit its growth potential in other diagnostic areas.
3. Vulnerability to Regulatory Changes: Quotient Ltd operates in a highly regulated industry, making it susceptible to changes in government policies and regulations that may impact its operations and market access.
Opportunities
1. Expansion into New Markets: Quotient Ltd has the potential to penetrate untapped markets such as emerging economies where there is a growing demand for advanced diagnostic solutions.
2. Strategic Partnerships and Acquisitions: Collaborations with strategic partners or acquiring complementary businesses can enhance Quotient Ltd's product portfolio and market reach.
3. Increasing Demand for Personalized Medicine: The trend towards personalized medicine presents an opportunity for Quotient Ltd to develop diagnostic tests tailored to individual patients, thereby addressing the evolving needs of the healthcare industry.
Threats
1. Intense Competition: The diagnostic testing market is highly competitive, with numerous established players and new entrants constantly emerging, posing a threat to Quotient Ltd's market share and pricing power.
2. Technological Advancements: Rapid advancements in technology may render Quotient Ltd's current testing platform obsolete if it fails to keep up with the pace of innovation.
3. Economic Instability: Economic downturns or fluctuations can impact healthcare spending, potentially leading to reduced demand for Quotient Ltd's diagnostic products and services.
Quotient Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Quotient Segments
Quotient Revenue by Segment
3 Years
5 Years
Max
Details
Quotient Revenue by Region
3 Years
5 Years
Max
Details
Quotient Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Quotient historical P/E ratio, EBIT multiple, and P/S ratio
Quotient annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Quotient shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Quotient stock splits
Current Quotient forecasts and price targets in August 2026
Analyst Price Targets 2026Quotient Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 6/29/2022 | Maintained | Outperform | 60 | |
| 6/29/2022 | Maintained | Buy | – | |
| 4/19/2022 | Maintained | Neutral | – | |
| 12/3/2021 | Maintained | Neutral | – | |
| 8/6/2021 | Maintained | Neutral | – | |
| 6/3/2021 | Maintained | Neutral | – | |
| 3/5/2019 | Maintained | Buy | 47 | |
| 11/1/2017 | Maintained | Buy | 47 | |
| 4/18/2017 | Maintained | Buy | – | |
| 2/9/2016 | Maintained | Buy | 51 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Quotient Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/8/2022 | -9.62USD | - | 9.74 MUSD | - | 2023 Q2 |
| 8/9/2022 | -8.26USD | - | 9.69 MUSD | - | 2023 Q1 |
| 6/24/2022 | -12.85USD | - | 8.30 MUSD | - | 2022 Q4 |
| 2/8/2022 | -10.89USD | - | 9.35 MUSD | - | 2022 Q3 |
| 11/15/2021 | -0.27USD | - | 8.84 MUSD | - | 2022 Q2 |
| 8/5/2021 | -0.27USD | - | 9.41 MUSD | - | 2022 Q1 |
| 6/1/2021 | -0.27USD | - | 8.93 MUSD | - | 2021 Q4 |
| 2/1/2021 | -0.29USD | - | 8.42 MUSD | - | 2021 Q3 |
| 11/2/2020 | -0.34USD | - | 8.02 MUSD | - | 2021 Q2 |
| 8/3/2020 | -0.34USD | - | 8.80 MUSD | - | 2021 Q1 |
Quotient shareholder structure
| % | Name |
|---|---|
11.94011% | |
7.48608% | |
6.81853% | |
6.71948% | |
4.53865% | |
3.68736% |
Quotient Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
80.80% | SEC ↗ | |
80.80% | SEC ↗ | |
80.80% | SEC ↗ | |
40.50% | SEC ↗ | |
40.50% | SEC ↗ | |
40.50% | SEC ↗ | |
39.50% | SEC ↗ | |
36.50% | SEC ↗ | |
18.90% | SEC ↗ | |
17.40% | SEC ↗ |
Quotient Supply Chain
Quotient Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.39 | 0.74 | 0.86 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Ortho Cli Dgnst Rg | 0.58 | 0.79 | — | |
| 2 | 0.87 | 0.04 | -0.78 | ||
| 3 | 0.91 | 0.68 | -0.37 | ||
| 4 | 0.79 | 0.57 | -0.13 | ||
| 5 | Open Orphan | 0.73 | 0.87 | 0.04 |
Frequently asked questions about Quotient
The business model of Quotient Ltd focuses on the development and commercialization of innovative transfusion diagnostics solutions. Quotient's MosaiQ™ technology platform enables the provision of a wide range of serological tests on a single system. This advanced platform merges automated microarray technology with proprietary chemistry and software, allowing for high-throughput testing and efficient resource allocation. With its unique offering, Quotient Ltd aims to enhance patient outcomes and optimize laboratory efficiency in the field of blood transfusion diagnostics.
Quotient Ltd is primarily active in the field of diagnostics and healthcare. As a global leader, Quotient specializes in developing innovative products and technologies for blood grouping and infectious disease testing. The company provides customized solutions to the blood transfusion and transplantation markets, ensuring the safety and accuracy of patient testing. With a focus on enhancing efficiency and reducing costs, Quotient offers a comprehensive range of products that cater to the needs of healthcare providers worldwide. Through their cutting-edge solutions, Quotient Ltd plays a crucial role in improving public health outcomes and supporting healthcare professionals in diagnosing and treating patients effectively.
Some of the main competitors of Quotient Ltd in the market include companies like Hologic Inc., Immucor Inc., and Grifols S.A. These companies also operate in the field of diagnostics and blood testing solutions, potentially competing with Quotient Ltd in terms of product offerings and market share. However, Quotient Ltd has built a strong reputation and market presence with its innovative technologies and services.
Quotient Ltd is a renowned company with a rich history and background. It was founded in 2007 and is headquartered in Eysins, Switzerland. Originally known as Inverness Medical Innovations, the company rebranded as Alere Inc. in 2011 before becoming Quotient Limited in 2017. Quotient is a commercial-stage diagnostics company that focuses on transforming transfusion diagnostics, delivering innovative products to optimize patient care. With its cutting-edge technology and expertise, Quotient aims to address unmet needs in blood typing and screening, helping to improve the safety and efficiency of transfusion medicine. Quotient Ltd continues to make significant contributions in the field of diagnostics and healthcare.
Quotient Ltd, a leading diagnostics company, has achieved several significant milestones. The company introduced MosaiQ, its game-changing platform which revolutionizes transfusion diagnostics. Quotient Ltd successfully launched the MosaiQ Early Warnings Score, a novel risk stratification tool for assessing disease severity in critically ill patients. The company also achieved CE Marking for the MosaiQ™ Zika and Calibrator Panel, reinforcing its commitment to advancing diagnostics for infectious diseases. Quotient Ltd's collaborations with renowned institutions have further contributed to its success, including partnerships with Ortho Clinical Diagnostics and the Red Cross. These milestones showcase Quotient Ltd's dedication to innovation and its impact on improving patient outcomes in the field of diagnostics.
Quotient Ltd is primarily present in various countries and regions across the globe. The company has a global presence, with significant operations in the United States, Europe, and Asia-Pacific. Quotient Ltd has established a strong foothold in these key markets, allowing it to effectively serve its customers and expand its reach. With a wide presence in multiple countries and regions, Quotient Ltd continues to strengthen its position as a prominent player in the stock market industry.
Quotient Ltd represents a set of core values and corporate philosophy that guide its operations. The company emphasizes innovation, aiming to develop and deliver novel solutions in the diagnostics field. With a strong focus on precision medicine, Quotient Ltd also prioritizes accuracy and reliability in its products and services. The company values collaboration and partnerships, continually seeking to forge relationships that drive advancements in healthcare. Furthermore, Quotient Ltd is committed to high ethical standards, ensuring transparency and integrity in its conduct. By embodying these values and corporate philosophy, Quotient Ltd strives to make a positive impact in the healthcare industry.
7 analysts currently rate the Quotient stock: 6 recommend buying, 1 holding and 0 selling.
The Quotient share (QTNT) is listed on 3 stock exchanges, including: NASDAQ (QTNT), Frankfurt (U4W.F), München (U4W.MU).
Quotient Ltd is a global company that offers innovative technologies and services for the pharmaceutical and biotech industry. The company employs over a thousand employees and is headquartered in Eysins, Switzerland. Its business model includes various divisions, with a focus on science, research, and the development of drugs and biotech products. The main areas of business are drug development services, manufacturing sciences & services, diagnostic solutions, immunoassays & bioassays, and digital health and AI. Quotient Ltd has developed a wide range of products for use in various fields, including assay ready cells, transfection reagents and electrodes, particle cleaning and analysis devices, and various assays and tests for genetic variations and drug determination. The company aims to push the boundaries of science and research and improve the effectiveness of drugs and biotech products. Through continuous investments in research and development, innovative technologies and services, and a focus on customer needs, Quotient Ltd has successfully positioned itself as a leading provider in the biotech industry. The company's $100 million in revenue and collaborations with global players such as GSK, Merck, and Sanofi attest to its economic success.
The revenue cannot currently be calculated for Quotient.
The profit cannot currently be calculated for Quotient.
The P/E ratio cannot be calculated for Quotient at the moment.
The P/S cannot be calculated for Quotient currently.
The Eulerpool Quality Score for Quotient is 4/10.
The ISIN of Quotient is JE00BLG2ZQ72. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Quotient is A11598. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Quotient is QTNT. The ticker symbol is used to trade Quotient shares on the stock exchange.
Quotient is assigned to the 'Health' sector.
The dividends of Quotient are distributed in USD.
Quotient stock
Quotient Peer Group
Quotient Ticker
All fundamentals and in-depth analysis of Quotient
Our stock analysis for Quotient stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quotient. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.